arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Latin America Healthcare and Life Sciences Summit 2016

Globalization and Innovation: Opportunity in a Transforming Healthcare Market

Miami |
Speakers include:
Nicholas  Osorio

Nicholas Osorio

Walgreens Boots Alliance

Barry Finette

Barry Finette

THINKMD

José Luis  Bruzadin

José Luis Bruzadin

Intel Corporation

Overview

The FT Latin America Healthcare and Life Sciences Summit, now in its second successful year, will provide a timely opportunity to examine and discuss the major trends shaping the public and private healthcare and life sciences industries of the region, as well as the emerging opportunities and challenges for investors.

It has been a year of both opportunity and challenge for the Latin America’s life science and healthcare industry. Currency depreciation and a slowing economy have constrained the ability of governments in the region to meet critical healthcare challenges. The Zika outbreak, meanwhile, has drawn attention to the enduring spectre of infectious diseases and the inadequacies of existing healthcare infrastructure, just as a growing epidemic of Non-Communicable Diseases (NCDs) threatens to overwhelm. Yet opportunities for investors in the region abound. Despite the current downturn, total healthcare expenditure is expected to grow significantly in the years ahead; international efforts will be needed to develop and finance vaccines, diagnostics and treatments for infection diseases; the scope for the private sector and for public–private partnerships can be expected to increase as cash-strapped governments try to fill critical infrastructure gaps, and products, service and solutions geared toward and the needs of region’s expanding elderly and chronically ill population –from new drugs, to home care and digital solutions- are a growing niche.

fallback
fallback Add to my Calendar 10/25/2016 08:00:0010/25/2016 17:45:00trueFT Latin America Healthcare and Life Sciences Summit 2016The FT Latin America Healthcare and Life Sciences Summit, now in its second successful year, will provide a timely opportunity to examine and discuss the major trends shaping the public and private healthcare and life sciences industries of the region, as well as the emerging opportunities and challenges for investors.It has been a year of both opportunity and challenge for the Latin America’s life science and healthcare industry. Currency depreciation and a slowing economy have constrained the ability of governments in the region to meet critical healthcare challenges. The Zika outbreak, meanwhile, has drawn attention to the enduring spectre of infectious diseases and the inadequacies of existing healthcare infrastructure, just as a growing epidemic of Non-Communicable Diseases (NCDs) threatens to overwhelm. Yet opportunities for investors in the region abound. Despite the current downturn, total healthcare expenditure is expected to grow significantly in the years ahead; international efforts will be needed to develop and finance vaccines, diagnostics and treatments for infection diseases; the scope for the private sector and for public–private partnerships can be expected to increase as cash-strapped governments try to fill critical infrastructure gaps, and products, service and solutions geared toward and the needs of region’s expanding elderly and chronically ill population –from new drugs, to home care and digital solutions- are a growing niche.FT-Latin-America-Healthcare-and-Life-Sciences-Summit-2016713429ff5d220b034e0c1b42e808152dMM/DD/YYYY

Brochure Download

Brochure Download

Download now

Event Brochure

To download the event brochure please fill in the form below. All fields are required

Please complete all the highlighted fields

Form submission failed. Please retry.

For more information about how we use your data please refer to our privacy and cookie policies.

Invites and offers from the FT

Receive exclusive personalised events invitations, carefully-curated offers, future speaking engagements and promotions from Financial Times Live

Thank you for submitting your details. Please download the event brochure.

Testimonials

"Great cross industry examination of future trends"
Edvard Philipson, Vice President - Latin America, Ferring Pharmaceuticals

"An amazing event that brought together specialists for relevant discussions regarding Healthcare in LATAM. The event was a great opportunity to increase awareness on relevant topics concerning HealthCare in LATAM, as it facilitated the share and leverage of information and expertise, a first step for generating smart solutions."
Maria Julia De Garcia, International Financial Advisor, Merrill Lynch

"A comprehensive and realistic discussion on healthcare in Latin America"
Leonardo Florencio, CEO, ePrimeCare

fallback

Follow us on Twitter:

Twitter 2

More

Speakers (23)

Nicholas  Osorio

Nicholas Osorio

Regional Manager Director, Latin America, International Retail
Walgreens Boots Alliance

Nicholas Osorio is the Regional Managing Director, Latin America, International Retail of Walgreens Boots Alliance. Mr Osorio oversees WBA’s retail businesses in the region with a particular focus on the company’s Latin America affiliate companies, Farmacias Benavides in Mexico and Famarcias Ahumada in Chile. He is an experienced Latin America and international business leader with over 20 years of expertise Europe in general management, commercial and marketing roles in Fortune 500 consumer packaged goods (CPG) firms throughout the Americas and Europe.  He joined WBA from TCC Global NV where he was Vice President and General Manager for Latin America. Prior to that Mr Osoria had various leadership roles with Newell Rubbermaid, which he joined in October 1997.

Barry Finette

Barry Finette

Founder
THINKMD

Barry Finette is a Professor of Pediatrics at the University of Vermont College of Medicine, and an Attending and Teaching physician in the Pediatric Inpatient and Critical Care Division at Vermont Children’s Hospital at the University of Vermont Medical Center. He is also the Director of the Global Health and Humanitarian Opportunity Program at the University of Vermont. He has 25 years of experience as a Pediatrician in the areas of emergency; critical and acute care medicine, with an additional 30 years of experience as a basic, clinical and translational research scientist. Over the last 7 years he has focused his work in the areas of Global Health and Humanitarian Assistance. He has participated in numerous research, medical and humanitarian capacity building and disaster relief missions in Uganda, Ethiopia, Peru, Jamaica, Bhutan, South Africa, Ecuador, Philippines, Congo, Cameroon, Togo, Benin, Bangladesh, and Burkina Faso. He is also the Founder THINKMD, Inc., a Vermont based “benefit corporation” whose mission is to expand healthcare equality and equality to everyone, everywhere. THINKMD’s initial product called MEDSINC, is an integrated, mobile point of care clinical assessment, triage and treatment tool focused to be used by community and frontline health workers in low resource countries in order to increase healthcare capacity where the humanitarian need is greatest.

José Luis  Bruzadin

José Luis Bruzadin

Senior Director, Latin America, Health and Life Sciences
Intel Corporation

José Luis Bruzadin is the Senior Director, Latin America, Health and Life Sciences, Intel Corporation. Mr Bruzadin leads all sales and marketing activity for health and life sciences in Latin America. His current role is dedicated to identifying ways to innovate the health sector in Latin America through the use of information and communications technology.  Among other projects in this area, Mr Bruzadin has led Intel's efforts to deploy telemedicine in the Amazon region. He has worked for Intel for the last 15 years. Before his work in the health and life sciences sector, Mr Bruzadin participated in the transformation of the Brazilian banking system through the use of information and communications technology, and later worked in the telecommunications industry. Mr Bruzadin  is a member of the FCS Brazil Health IT Strategic Advisory Committee and is a recognized and regular speaker at Health and Life Sciences events throughout Latin America. He is an Electronics Engineer who graduated from the Polytechnic School of the University of São Paulo, Brazil and holds a postgraduate degree in Marketing Management from Fundação Giulio Vargas.

Pablo   Kuri Morales

Pablo Kuri Morales

Undersecretary of Prevention and Health Promotion
Secretariat of Health, Mexico

Pablo Kuri-Morales M.D. earned his medical degree from the National Autonomous University of Mexico (UNAM). He holds a Master’s Degree in Science and specialized in Public Health certified by the Specialty Council (Consejo de Especialidad). He also received a Diploma in international public health from Emory University in Atlanta, Georgia, collectively with the CDC; and completed the Special Program for Senior Executives at the IPADE Business School.

He served as General Director of the National Center for Epidemiological Surveillance and Disease Control (CENAVECE), as well as of the Epidemiology Department at the Federal Health Ministry.

Since 1986 he has been teaching at UNAM’s Medical School, supervising academic research on diverse topics, and educating outstanding health specialists including epidemiologists.

He was President of the Public Health Mexican Society (Sociedad Mexicana de Salud Pública) and is member of the Mexican Surgery Academy (Academia Mexicana de Cirugía) and the National Academy of Medicine where he served as Deputy Secretary.

Dr. Kuri has published more than 125 articles related to epidemiology, addiction prevention, and public health policies.

He has also experience in the private sector in which he worked from 2009 to 2011.

Since December 2011, he has been acting as Undersecretary of Prevention and Health Promotion at the Ministry of Health for the Federal Government of Mexico.

Dr. Pablo Kuri is recognized as a leading expert in national and international attention, response and resolution of emergencies caused by natural disasters, pandemics and health security. He has been in charge of Mexico's response to threats such as Anthrax, SARS, influenza and Ebola, with a successful participation in more than 20 mayor field operations.

He has several awards related to his professional career.

Dr Carissa  Etienne

Dr Carissa Etienne

Director
Pan American Health Organization

Dr Carissa Etienne was elected in 2012 as the new Director of the Pan American Health Organization/World Health Organization (PAHO/WHO) by the PAHO Member States. From 2008 to 2012, she was Assistant Director-General of the Health Systems and Services’ Cluster of the World Health Organization in Geneva, Switzerland. Prior to that, she was Assistant Director of the Pan American Health Organization from July 2003 to February 2008. As Assistant Director in PAHO, she directed five technical areas - health systems and services; technology and health services delivery; health surveillance and disease management; family and community health; and sustainable development and environmental health. During her tenures at WHO and PAHO, Dr Etienne has led the renewal of primary health care and the strengthening of health systems based on primary health, promoting integration and improved functioning of health systems. She has also spearheaded policy directions to reduce inequalities and advance health for all through universal coverage, people-centred care, the integration of health into broader public policies, and inclusive and participatory health leadership. A national of Dominica, Dr Etienne began her career as a medical officer at the Princess Margaret Hospital in her country, where she eventually became the Chief Medical Officer. Other high-level posts she has held include Coordinator of Dominica’s National AIDS Program, Disaster Coordinator for the Ministry of Health of Dominica, Chairperson for the National Advisory Council for HIV/AIDS, and Director of Primary Health Care for Dominica. Dr Etienne received her MBBS degree from the University of the West Indies, Jamaica, and her MSc. degree in community health in developing countries from the London School of Hygiene and Tropical Medicine, University of London.

Roberto Tapia-Conyer

Roberto Tapia-Conyer

Chief Executive Officer
Carlos Slim Foundation

Roberto Tapia-Conyer is Chief Executive Officer of the Carlos Slim Foundation and member of the Permanent Advisory Board of the Mexican Society of Public Health, member of the Mexican National Academies of Medicine and Surgery, the Mexican Academy of Sciences and the National Research System. Dr Tapia-Conyer is also member of the high-level advisory board of the University of California’s Mexico Initiative; the Steering Committee Partnership for Dengue Control and the International Task Force for Disease Eradication at The Carter Center. He is a tenured Professor at the UNAM’s School of Medicine, and has been visiting Professor at the University of California’s (UC) campuses in San Francisco and Irvine. He is now also a Visiting Professor at the UC campus in Berkeley. Dr Tapia-Conyer previously served in México’s Ministry of Health which he joined in 1982. From 1997 to 2006 he served as Vice-Minister of Prevention and Promotion, having under his scope of responsibility the design and development of innovative and effective public health policies and programs Dr Tapia-Conyer graduated as a Medical Doctor from the National University of Mexico (UNAM). He holds Masters degree in Science and Public Health from Harvard University, as well as a Doctorate in Sciences.

Peter Sands

Peter Sands

Executive Director
The Global Fund

Peter Sands has been the Executive Director of The Global Fund for AIDS, Tuberculosis and Malaria since March 2018.

Since June 2015 Peter has been a Research Fellow at Harvard University, dividing his time between the Mossavar-Rahmani Center for Business and Government at Harvard Kennedy School and the Harvard Global Health Institute.

Peter was Group CEO of Standard Chartered PLC from November 2006 to June 2015, having joined the Board of Standard Chartered as Group CFO in May 2002.

Prior to joining Standard Chartered, Peter was a Senior Partner at McKinsey & Co.

Peter has served on various boards and commissions, including as Lead Non-Executive Director of the UK Department of Health, Director of the World Economic Forum/Davos, Member of the International Advisory Board of the Monetary Authority of Singapore, Member of the China People’s Association for Friendship with Foreign People’s Global CEO Council, and Co-Chair of the UK-India CEO Forum.

Peter graduated from Oxford University with a First-Class degree in Politics, Philosophy and Economics. He also received a Master in Public Administration from Harvard University, where he was a Harkness Fellow. Peter, who grew up in Singapore and Malaysia, is married to author and bookshop owner, Betsy Tobin and has four children.

Gary  Nabel

Gary Nabel

Chief Scientific Officer for Global Research & Senior Vice President
Sanofi

Dr Gary Nabel is Chief Scientific Officer for Global Research and Development at Sanofi. He also serves as Senior Vice President for the company. An author of more than 400 scientific publications, Dr Nabel joined Sanofi in 2012 from the National Institutes of Health, where he served as Director of the Vaccine Research Center (VRC) since1999, during which time, he provided overall direction and scientific leadership of the basic, clinical, and translational research activities and guided development of novel vaccine strategies against HIV and other emerging and re-emerging infectious diseases. Dr Nabel graduated magna cum laude from Harvard College in 1975 and continued his graduate studies at Harvard, completing his PhD in 1980 and his MD two years later. In recognition of his expertise at the forefront of virology, immunology, gene therapy, and molecular biology, Dr Nabel was elected to the Institute of Medicine of the National Academy of Sciences in 1998. Among his many other honors, Dr Nabel received the Amgen Scientific Achievement Award from the American Society for Biochemistry and Molecular Biology, the Health and Human Services Secretary’s Award for Distinguished Service, and is a fellow of the American Association of Physicians, and the American Academy of Arts Sciences.

Anita  Cava

Anita Cava

Professor, Business Law Department Director, Business Ethics Program School of Business Administration Co-Director, UM Ethics Programs
University of Miami

Anita Cava is the Director of the Business Ethics Program and Co-Director of the University of Miami Ethics Programs, a university-wide entity that promotes research, teaching and service across the disciplines in areas of ethical interest and concern. Her current research interests are the legal and ethical aspects of health administration as well as corporate/community engagement and business ethics, with a focus on international corruption. Professor Cava is the Academic Director of the School of Business Latin American Health Care Compliance Certificate Program and created the School’s innovative Compliance Boot Camp for undergraduate students.  She is an active member of the Latin American Ethics and Compliance Network and the Anti-Corruption Interest Group of the American Society of International Law.

Christopher  Thibodeau

Christopher Thibodeau

Chief Commercial Officer & EVP of Commercial Operations
MDxHealth
Mohan Chellappa

Mohan Chellappa

President, Global Ventures and Executive Vice President
Johns Hopkins Medicine International

Dr Mohan Chellappa is the President, Global Ventures, and Executive Vice President, Johns Hopkins Medicine International. A founding member of Johns Hopkins Medicine International since 1997, he is involved in the development of international clinical consultancy activities, especially in the area of clinical care program development, quality systems implementation and utilization of information technology in healthcare. Dr Chellappa has been instrumental in securing and establishing various clinical, management and enterprise developmental initiatives and engagements of Johns Hopkins Medicine globally. One of his notable achievements is the establishment of Johns Hopkins Aramco Healthcare, a joint venture between Johns Hopkins Medicine International and Aramco, the world’s largest energy company. A surgeon by profession, he is a Fellow of the Royal College of Surgeons Edinburgh and Fellow of the American College of Surgeons, in addition to holding a business degree. He has a wide surgical experience, having worked in countries such as India, Malaysia, Singapore, UK and USA. Dr Chellappa pioneered laparoscopic gastrointestinal surgery in Asia and subsequently provided training in laparoscopic techniques to many surgeons from the Mid-East and Asia Pacific Region. Through his training programs, he established a broad network of contacts with the Medical community in these countries. He serves on the board of Johns Hopkins Aramco Healthcare KSA (Saudi Arabia) and HCL Healthcare (India).

Nanette  Cocero

Nanette Cocero

Regional Head of Latin America, Global Innovative Pharma Business (GIPB)
Pfizer Innovative Health

Nanette Cocero was appointed the Regional President of Emerging Markets for Pfizer’s Innovative Health business in June 2016. As the leader for the Emerging Markets business, Ms Cocero oversees business operations in Latin America, Africa and the Middle East, and emerging Asia markets. Previous to this role, Ms Cocero was the Regional President of Pfizer’s Latin America Global Innovative Pharma Business Unit. Additionally, her previous roles at Pfizer have included leading the Specialty and Oncology portfolio for Emerging Markets and the Specialty Care Business in Spain, as well as heading the regional marketing team for Latin America. During her 15 year tenure at Pfizer, Ms Cocero has contributed to continuous growth for the businesses she managed, which included launching and creating access to innovative medicines for the patients that need them. She has successfully launched a series of new products in multiple markets, representing important medical breakthroughs in disease areas such as pain management, oncology, rheumatoid arthritis and cardiology. Prior to joining Pfizer, Ms Cocero worked for 10 years as a management consultant, specializing in market research, financial modelling, and strategy development for the pharmaceutical and biotechnology industries. Additionally, as Research Fellow for the University of Pennsylvania Department of Pharmacology, she consulted for major pharmaceutical companies performing research for FDA Review. Ms Cocero earned a Bachelor of Science degree in Chemistry from Cornell University; a PhD. in Pharmacology from the University of Pennsylvania, and an MBA from The Wharton Business School.

Xavier  Urtubey

Xavier Urtubey

CEO and Co-Founder
AccuHealth

Xavier Urtubey is Co-Founder and CEO of AccuHealth, a healthcare tele monitoring company that operates across the care continuum through the provision of a high added-value service supported by a data-mining / predictive modelling proprietary platform. The company creates medical evidence from over 8.000 individuals monitored with personalized international protocols, and its initiatives have resulted in a significant fall in major complications for patients in pre-hospital stages and the avoidance of 70-80% of Emergency Room visits. Today, with 3.800+ chronic patients/month, AccuHealth has embarked on a program of international expansion. Mr Urtubey has more than 25 years of experience in the connected health arena. Previously, he was a Telehealth Expert for several United Nations agencies, national governments (France, US, Canada), the World Bank and the Inter-American Development Bank. He is principal author of Telehealth in the Americas (OAS - ITU - PAHO/WHO). He currently Chairs the American Telemedicine Association’s (ATA) Latin American Chapter.

Antonio Bouzada

Antonio Bouzada

President
Eriochem

Antonio Bouzada is President of Eriochem SA, a company he founded in 1998. This dynamic Argentinian pharmaceutical company has since expanded its business to other parts of the Americas where its affiliate businesses operate as Eriochem Science Zone SA in Urgaguay, as Eriochem Zenitec in Brazil, as Eriomex SA in Mexico and as Eriochem USA in the United States. From 1996 to 1998, Mr Bouzada was General Manager of Serono Argentina SA. Prior to this, from 1985 to 1998, he founded and directed Laboratorios Filaxis SA. Mr Bouzada has also created several agribusinesses in Argentina, to include San Fernando SA (Argentina), Paraje Rocío SA and Pondesur SA (Argentina and Uruguay). He has established a number of important agriculture producer’s groups in Argentina, where he has very actively promoted the use of new technologies. Mr Bouzada is co-author of several patents which were registered and submitted in various markets to include the USA, Europe, Argentina and other countries of Latin America. He is a regular speaker at university and association events relating to the governance of Innovation and science in Argentina, where he emphasizes the importance of innovation and education and their correlation with business improvement. Mr Bouzada received a Law degree in 1976 from the Universidad Nacional del Litoral (Santa Fe, Argentina).

Marcos  Espinal

Marcos Espinal

Chief Of Department of Communicable Diseases and Health Analysis
Pan American Health Organization (PAHO)

Dr. Marcos A. Espinal is currently the Director of the Department of Communicable Diseases and Health Analysis at the Pan American Health Organization (PAHO), Regional Office for the Americas of the World Health Organization (WHO). Dr Espinal’s portfolio includes five major areas: neglected, tropical & vector-borne diseases; international health regulations, epidemic alert & response, risk and outbreak communication; HIV, Hepatitis, TB & STIs; health information & analysis; and veterinary public health. Dr Espinal, a national of the Dominican Republic, holds a medical degree from the Universidad Autónoma de Santo Domingo, Dominican Republic (1985); he is a pediatrician, with three years of residency at the Robert Reid Children’s Hospital of Santo Domingo, Dominican Republic. He obtained a master’s degree in public health (1990) and a doctorate in public health (1995) from the University of California at Berkeley School of Public Health.

Dr. Espinal’s work experience includes positions in the Ministry of Health of the Dominican Republic and the National Center for Research on Maternal and Child Health; the New York City Public Health Department; and the WHO where he worked for 13 years. Before joining PAHO, Dr Espinal served as Executive Secretary of the WHO Stop TB Partnership, a global movement aiming at the elimination of TB as a public health problem.

Dr. Espinal has published more than 100 publications in the field of communicable diseases. He is associate editor of the International Journal against TB and Lung Disease and reviewer for numerous journals including Lancet, JAMA, Journal of Infectious Diseases, New England Journal of Medicine, among others. His work has transcended beyond the field of medicine and public health worldwide when he was cited by the renowned author John Le Carré in his book The Constant Gardener. In 2006 together with Bill Gates, Gordon Brown, Chancellor of England, and Olusegun Obasanjo, President of Nigeria, Dr Espinal launched the Global Plan to Eliminate Tuberculosis at the World Economic Forum in Davos, Switzerland.

He is a recipient of the Scientific Prize of the International Union against Tuberculosis and Lung Diseases, the Albert and Mildred Krueger Memorial Fellowship, and a graduate scholarship from the John E. Fogarty International Center. In 2008, Dr. Espinal was awarded the Walter and Elise A. Hass International Award by the University of California at Berkeley for a distinguished record of service in international health; and in 2012, he was awarded the Princess Chichibu Memorial TB Global Award by the Japan Anti-Tuberculosis Association, in Kuala Lumpur, Malaysia, at the World Congress on Lung Health and Respiratory Diseases. In 2015 he was recognized by the American Chamber of Commerce of the Dominican Republic for his work and outstanding career in the field of research, public health, and pediatrics.

Karissa  Price-Rico

Karissa Price-Rico

President, Emerging Business Division
Healthways

Karissa Price-Ricois the President of the Emerging Businesses Division of Healthways, a subsidiary of Sharecare Inc. She has P & L responsibility for three growth businesses: Blue Zones Project, Ornish Reversal Program and Healthways Diabetes Service. She is also responsible for Healthways strategic partnerships with Gallup and the Gallup- Healthways Well Being Index and a partnership with Johns Hopkins University. Dr Price-Rico is a strategic leader with broad industry experience across entertainment, consumer products and healthcare. She has been a consultant for Fortune 100 companies, a co-founder of a healthcare start-up, and lead product development, marketing, business development and strategy for a healthcare technology joint-venture between Intel and GE. A graduate of Harvard University, Dr Price-Ricoholds a Doctorate degree in International Political Economy.

Gerardo Cárdenas Vogel

Gerardo Cárdenas Vogel

Director General and CEO
Innovare R&D

Gerardo Cárdenas Vogel is Chief Executive Officer of Innovare R&D, a position he assumed in November 2012. Under his leadership, Mr Vogel has overseen a 20-fold increase in sales, and the transition of the company into one of Mexico’s very few innovation and research focused pharmaceutical companies. With expertise in pharmaceutical license valuation and negotiation, along with a strong understanding of development and regulatory processes, both local and international, Mr Vogel is now leading Innovare R&D in a new venture to help develop early-stage drug assets in a very supportive clinical research environment.  Mr Vogel joined the company in 2008 as the Head of Business Development and negotiated a strategic alliance with the French specialty pharmaceutical company, LFB, in 2011.  Mr Vogel´s has a degree in Chemical Engineering from the Universidad Iberoamericana in Mexico City, with specialization in Organometallic-mediated Synthesis.

Alejandro Tocigl

Alejandro Tocigl

CEO
Mirocolus

Alejandro Tocigl is Co-founder and CEO of Miroculus. Prior to this, he acted as the CEO of a high- tech company in Chile as part of his responsibilities while working at a venture capital fund in Latin America. Among his accolades, he was selected to be among the 100 young leaders of Chile 15' and was ranked among the top Innovators by MIT TR35.He graduated from the Faculty of Economics & Business, Universidad de Chile, completed his studies at ESSEC, Paris and attended the Graduate Studies Program 2013 at Singularity University, Nasa Ames, USA.

Morten Vaupel

Morten Vaupel

General Manager
Novo Nordisk

Born in Copenhagen (Denmark), Morten Vaupel holds a Bachelor Degree in Economics and a Master’s in International Business from the Copenhagen Business School. Additionally, he has studies from London and Barcelona.

His professional career started over two decades ago in Novo Nordisk. He started in the Finance Department of the Region Europe Office, where he was later appointed as Head of the Customer Service Department.

In 2000, he served as Marketing Effectiveness Project Leader for the United States, Australia, Spain and the United Kingdom.

In 2002, he assumed the position of Diabetes Marketing Director for the Eastern European countries based in Warsaw (Poland). Three years later, in 2005, he was appointed biopharm vice president for Region Europe, based in Zurich (Switzerland).

From 2007 to 2012, he worked as General Manager for Hungary and Baltic countries, based in Budapest (Hungary).

He was appointed vice president and General Manager for Mexico in 2012, where he currently heads up an affiliate strong of 220 employees and where he has launched the company´s most innovative products for the treatment of diabetes and obesity.

Jose Maria  Garcia-Soto

Jose Maria Garcia-Soto

Director Integrated Health Solutions Latin America
Medtronic

Jose Maria Garcia-Soto is the Director of Integrated Health Solutions for Medtronic Latin America, a position he has held since 2012. In this role, Mr Garcia-Soto has successfully addressed the challenges of developing innovative value-based healthcare business models and building collaborative partnerships with hospitals to increase efficiency, quality and reach of healthcare to benefit patients, payers and governments across the region. Prior to this, from 2011, Mr Garcia-Soto worked in the commercial strategy function for EMEA (Europe, Middle East and Africa) for Medtronic Switzerland. Mr Garia-Soto also serves on the Board of Directors for Cardiored, a healthcare solutions company acquired by Medtronic in Chile.  Prior to joining Medtronic, Mr Garcia-Soto worked for five years at Maersk Line in Spain, Portugal, Denmark and France, holding a variety of leadership positions across both operational and commercial functions. Mr Garcia-Soto holds a Bachelor’s degree in Business Administration from the European Business School and a Master's degree in Business Administration from IESE Business School, Universidad de Navarra and UCLA Anderson School of Management. 

Wilson  Savino

Wilson Savino

Director
Oswaldo Cruz Institute

Wilson Savino is Director of the Oswaldo Cruz Institute, at the Oswaldo Cruz Foundation (Fiocruz) in Rio de Janeiro. He is an experienced researcher with expertise in the field of Immunology and Cell Biology, and currently coordinates a network of scientists in the State of Rio de Janeiro with a focus on microcephaly and congenital infection linked to the Zika virus. He had also been the Editor-in-Chief of the scientific journal NeuroImmuno Modulation since 2007. Dr Savino is member of the Brazilian Academy of Sciences and of the International Scientific Board of the Pasteur Institute of Montevideo. He is a past President of the Brazilian Society of Immunology (1993-1994) and the Brazilian Society of Cell Biology (2010-2014). He has been the recipient of several awards and honors including the title of "Chevalier dans l'Ordre de Palmes Académiques" awarded by the French government, and the Luis Federico Leloir medal, awarded by the Argentinian government. Dr Savino Graduated in Biological Sciences at the State University of Rio de Janeiro (1974), obtained the Master’s degree in Histology and Embryology at the Federal University of Rio de Janeiro (1979) and a PhD in Cell and Tissue Biology at the University of São Paulo (1982). He completed his post-doctorate training in Cellular Immunology at the Necker Hospital, Paris (1983-1985).

Phil Pfrang

Phil Pfrang

Global Leader, Life Sciences & Health Care (LSHC) Financial Advisory
Deloitte Touche Tohmatsu Limited

Phil Pfrang is Global Leader, Life Sciences & Health Care (LSHC) Financial Advisory, Deloitte Touche Tohmatsu Limited.  He also serves as Managing Partner for LSHC M&A Transaction Services for Deloitte United States.  During his 29 year career, Mr  Pfrang has assisted numerous clients with completed or proposed transactions in a broad cross-section of sectors including medical devices/supplies, acute care hospitals, surgical facilities, outpatient facilities, skilled nursing facilities, durable medical equipment, home health, infusion therapy, psychiatric/behavioral care, physician staffing and physician practice management, managed care, Medicare Advantage, disease management, pharmaceuticals, pharmaceutical services, pharmacy, pharmacy benefit management companies and health care IT providers. As part of his leadership roles, he has served many of Deloitte’s most important strategic and private equity clients.  He also has extensive experience in international and cross-border transactions.

Raman Singh

Raman Singh

President, Emerging Markets
Mundipharma

Based in Singapore, Raman Singh was appointed President of Mundipharma Asia Pacific, Latin America, Middle East and Africa, in October 2011. Mr Singh oversees all aspects of the Mundipharma businesses across these territories, which operate as a network of independent companies and leaders in pain management. Prior to this appointment, Mr Singh was the Vice-President of Commercial Operations for Emerging Markets at GlaxoSmithKline, based out of London, where he was in charge of overseeing all aspects of the brand’s Commercial operations across its emerging markets. He has previously held positions in Abbott as the Regional Director in Australia and New Zealand, and General Manager for Korea. He has also held various sales, marketing and strategy positions in Bayer. Mr Singh holds an MBA from Thunderbird, the American Graduate School of International Management.

fallback

Chaired by (3)

David  Crow

David Crow

Senior US Business Correspondent
Financial Times

David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.

Mr Crow has an MA in English Literature from the University of Glasgow.

John Paul Rathbone

John Paul Rathbone

Latin America Editor
Financial Times

John Paul Rathbone was appointed Latin America Editor in April 2010, having previously edited the FT's Lex column. He joined the FT in 2008 from Breaking Views, where he was a financial commentator for several years and founding correspondent. Prior to that, he worked at Reuters and the World Bank. Mr Rathbone is a graduate of Oxford University, where he read Anthropology, and Columbia University, where he earned a Master's in Economics. He became a senior member of St Antony’s College, Oxford, in 2006. He is the author of The Sugar King of Havana: the rise and fall of Julio Lobo, Cuba's last tycoon.

Mitchell  Morris

Mitchell Morris

Global Life Sciences and Healthcare Industry Leader
Deloitte

Mitchell Morris is the global leader for the life sciences and health care industry as well as the global leader for the health care sector of Deloitte Touche Tohmatsu Limited (Deloitte). Additionally, he is Vice Chair and sector leader for health care providers for Deloitte in the United States. Dr Morris has more than 30 years of health care experience in consulting, health care administration, research, technology, education, and clinical care. Dr Morris’s focus has been on health systems, academic organizations, and government agencies, assisting them with the development and implementation of strategies around reform, operations, clinical programs and quality, IT and finance. Earlier, he served as a Senior Vice President of Health Systems and Chief Information Officer at MD Anderson Cancer Center where he was also Professor in Gynecologic Oncology and in Health Services Research.

Who Attends?

The FT Latin America Healthcare and Life Sciences Summit will be attended by: CEOs, CFOs, CIOs, Chief Medical Officers, Chief Strategy Officers, Heads of R&D, Emerging Markets or Latin America, Global Public Health, Consumer Health, Government Relations, Pricing, Regulation, Market Access and other senior-level executives in the following sectors:

  • Pharmaceuticals, Biotechnology, Generic and Specialty Pharmaceutical companies
  • Medical Devices and Diagnostics
  • Investments (Fund Managers, Venture Capitalists, Private Equity firms, Investment Bankers, IP Groups)
  • Healthcare Provider and Payers
  • Clinical Research Organizations
  • Healthcare IT and Digital Health (Patient records, data, mobile and telehealth applications, social media)
  • Regulation
fallback

Why Attend

  • Assess the implications of the current economic downturn for investment and innovation in healthcare in the region
  • Share perspectives with fellow investors on why Latin America is still the right place to invest, and the next big opportunities
  • Discover how Latin America’s healthcare companies are successfully transitioning from local to regional to innovative global players, and the implications for competitive landscape of the industry
  • Hear from the region’s digital health pioneers how digital disruption is taking hold, enabling innovative new business models to address the enduring challenges of costs, access and affordability  
  • Keep abreast of the new communicable and emerging NCD disease trends in the region and the lessons for addressing global public health challenges 
  • Meet and greet the local players and government decision makers who are transforming the healthcare markets of the region
fallback

Why Sponsor?

  • Gain access to senior decision makers across the full spectrum of the healthcare industry
  • Brand alignment with the FT and its unrivalled credibility
  • Demonstrate thought leadership around the current critical issues affecting the healthcare sector
  • Benefit from sustained international visibility through our advertising and marketing campaigns
fallback

Agenda - 25th Oct

  • 8:00am
    Breakfast and Registration
  • 9:00am
    Opening Remarks from the Chair:

    David Crow, Senior US Business Correspondent, Financial Times

  • 9:05am
    Keynote Opening Address

    Carissa Etienne, Director, Pan American Health Organization (PAHO)

  • 9:30am
    Panel: Re-Energizing Healthcare in Latin America- Next Frontiers for Healthcare Reform and Innovation

    How will the current economic downturn impact investment in healthcare and innovation in Latin America countries? Will we see governments turn increasingly to the private sector the fill the gaps? How open are Latin America countries to innovation in healthcare? How are the global megatrends in health-for instance the transition to more integrated health, the rise of healthcare consumerism, healthcare rationing /HTA playing out in Latin America? What are the key epidemiological and demographic trends, the unmet needs and emerging opportunities for healthcare and life sciences in Latin America? What is the ‘unfinished businesses’ of health throughout the region-the key remaining challenges, and the new challenges presented by the UN Sustainable Development Goals? What are the learnings from Latin America healthcare reforms and experiences for other countries?

    Carissa Etienne, Director, Pan American Health Organization (PAHO) 

    Roberto Tapia-Conyer, Chief Executive Officer, Carlos Slim Foundation

    ModeratorMitchell Morris, Global Life Sciences & Health Care Industry Leader, Deloitte

  • 10:20am
    21st Century Public Health Challenges in Latin America - Zika and Beyond: The Enduring Spectre of Communicable Diseases

    Both Ebola and recent Zika outbreak have cast a light on the enduring health challenges and consequences of infectious diseases in Latin America and around the world. Over 36 million people worldwide are infected with HIV, 2bn with TB, and 300-500 million new cases emerge each year of malaria. The Zika virus has already spread to 23 countries across the Americas.  Add to this the potential for new public health threats such as flu pandemics, antimicrobial resistance (AMR), and climate induced infections, and the scale of the challenge are potentially immense. The systems to manage it, meanwhile, are ‘woefully inadequate’. Regional as well as International efforts will be needed to build resilient healthcare and governance systems focused on prevention, surveillance and disease management and to encourage and incentivise sustainable investment in R&D, diagnostics , vaccines and treatments. 

    • Global and Latin America public health risks: what can we expect in future?
    • Will the world be able to forestall the next big pandemic?
    • Countering pandemic risk : implications for global and Latin America health architecture-building a resilient healthcare infrastructure
    • Filling the R&D vacuum: opportunities for collaboration for diagnostics, vaccines, treatments
    • A proactive research agenda: what are the mechanisms for financing and developing vaccines, diagnostics and treatments for potential emerging public health threats?

    Session Keynote: Peter Sands, Chair, Commission on a Global Health Risk Framework for the Future; Senior Fellow, Harvard Kennedy School

    Marcos Espinal, Head of Department of Communicable Diseases and Health Analysis (CHA), Pan American Health Organization

    Wilson Savino , Director , Oswaldo Cruz Institute 

    Gary Nabel, Senior Vice PresidentChief Scientific Officer, Sanofi

    Moderator: John Paul Rathbone, Latin America Editor, Financial Times

     

  • 11:10am
    Networking Coffee Break
  • 11:25am
    Panel: Non-Communicable Diseases (NCDs)-A Rising Health Emergency in Latin America

    In common with a great many regions across the world, the incidence of Non-Communicable diseases (NCDs) is rising in Latin America to unprecedented levels-a factor of growing urbanisation, an aging population and lifestyle changes as a by-product of increasing wealth and development. Some 56% of Latin Americans citizens are obese, well above the global average of 34%. Chronic diseases today already account for 65% of deaths in Latin America, a figure expected to rise to 81% by 2050. Innovations are already underway across the region to tackle the trend, but much more remains to be done:

    • What are the epidemiological trends for NCDs in Latin America?
    • What are the measures and initiatives which could reverse or stabilise the NCD trend-lesson from Latin American and international experiences? What works and doesn’t work?
    • What are the pioneering initiatives in Latin America and internationally which are having the biggest/have the potential to have the biggest impact?
    • To what extent are healthcare systems and strategies of healthcare and life sciences companies across the region evolving to meet the challenge? What more need to happen e.g. integration of health services and teams across the healthcare value chain ;collaboration between payers, providers and patients; the provision of care and health management solutions focused around patient needs; community and employers focused initiatives , innovative service delivery models and the adaption of primary care to the realities of NCDs? Population health strategies and approaches
    • Aligning healthcare providers across the spectrum for improved health ; what are the barriers and how can trust be built to enhance prospects for multi-stakeholder collaborations

    Pablo Antonio Kuri Morales, Undersecretary of Prevention and Health Promotion Secretariat of Health, Mexico

    Morten Vaupel, Vice President and General Manager, Novo Nordisk Mexico

    Jose Maria Garcia-Soto, Director Integrated Health Solutions Latin America, Medtronic

    Karissa Price, President, Emerging Business Division, Healthways

    Moderator: David Crow, US Senior Business Correspondent, Financial Times

  • 12:15pm
    Rising Expectations: A Profile of Healthcare Consumers in Latin America

    Nicholas Osorio, Regional Managing Director, Latin America, International Retail, Walgreens Boots Alliance

  • 12:35pm
    Lunch
  • 1:40pm
    Globalization and Innovation: The Future of Life Sciences in Latin America
    • Beyond global exports, will we see Latin America pharmaceutical life sciences and healthcare companies emerge as major players in the global healthcare market?
    • What are the challenges to innovation (e.g. regulation, incentives) and how can they be addressed?
    • What are the niches/therapy areas with the greatest opportunity for success in Latin America?
    • How are the strategies of Latin American life science companies impacted/evolving in reaction to global trends (for instance, the rise of patient expectations, regulation, pricing trends, rise of high price biologics and orphan drugs, etc?)
    • What are the prospects for biosimilars, and is success in biosimilars a precursor to further moves towards becoming true drug innovators?
    • Will the region successfully exploit its significant biodiversity potential for success in plant/animal base biotech?

    Session Keynote:The Path to Globalization: A Local Life Science Company's Journey

    A local Latin American life sciences company which has successfully embarked on the road to globalisation tells the story of the challenges on the way from local to regional to global player

    Antonio Bouzada, President, Eriochem 

    Followed by Panel Discussion:

    Gerardo Cárdenas Vogel, Chief Executive Officer, Innovare R&D

    Alejandro Tocigl, CEO, Mirocolus

    Moderator: David Crow, US Senior Business Correspondent, Financial Times 

  • 2:30pm
    Panel: Digital Health Hype and Reality-A Latin American Perspective

    Our panel will feature some of the region’s leading digital pioneers, entrepreneurs as well as public and private payers, who will share front-line experiences and perspectives on key issues to include: to what extent is digital disruption taking hold in Latin America healthcare markets? How are digital innovations enabling the emergence of new and innovative business models, and achieving the objectives of improving affordability, access, and reducing costs to the system? What are the main challenges in ensuring widespread uptake-for instance gaining the acceptance of payers, physicians and patients? 

    Xavier Urtubey, Co-Founder and CEO, AccuHealth; Chair, Latin-American & Caribbean Chapter, American Telemedicine Association

    José Luis Bruzadin, Senior Director, Latin America, Health and Life Sciences, Intel Corporation

    Barry Finette, Founder, THINKMD

    Moderator: David Crow, US Senior Business Correspondent, Financial Times

     

  • 3:15pm
    Investor Forum:Is Latin America Still the Right Place to Invest?

    Presentation: The Macroeconomic Outlook for Latin America and Implications for Healthcare/Healthcare Investment

    Phil Pfrang, Global Leader, Life Sciences & Health Care (LSHC) Financial Advisory, Deloitte Touche Tohmatsu Limited

    Panel: Market Entry Strategies and Access

    Nanette Cocero, Regional President, Emerging Markets, Pfizer Innovative Health

    Mohan Chellappa, President, Global Ventures and Executive Vice President, Johns Hopkins Medicine International

    Raman SinghPresident, Asia Pacific, Latin America, Middle East & North Africa, Mundipharma

    Presentation: Ethics and Compliance in a New Era of Transparency

    Professor Anita Cava, Director, Business Ethics Program; Co-Director, University of Miami Ethics Programs

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

     

     

  • 4:30pm
    Closing Remarks from the Chair
  • 4:35pm
    Networking Drinks Reception

Exhibitor (1)

FDA is responsible for protecting the public health by assuring the safety, efficacy and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation.

FDA is also responsible for advancing the public health by helping to speed innovations that make medicines more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medicines and foods to maintain and improve their health. FDA also has responsibility for regulating the manufacturing, marketing and distribution of tobacco products to protect the public health and to reduce tobacco use by minors.

The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This work covers more than just medicines. For example, fluoride toothpaste, antiperspirants, dandruff shampoos and sunscreens are all considered "drugs."

Lead Sponsor (1)

The Mundipharma global network of privately-owned independent associated companies (‘Mundipharma’) is equivalent to a mid-sized global pharmaceutical company. Central to our success is our focus on partnerships. We partner to accelerate the delivery of medicines to patients with unmet medical needs. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries, employing over 8,600 people.

Cocktail Reception Sponsor (1)

Enterprise Florida, Inc. (EFI) is a public-private partnership between Florida’s businesses and government leaders and is the principal economic development organization for Florida. EFI facilitates job growth for Florida through business recruitment and retention, international trade and export assistance, and more.  Enterprise Florida staff can provide confidential assistance to companies making location, relocation, or expansion decisions.

Supporting Partners (2)

PharmaBoardroom.com’s detailed country-specific reports - Healthcare and Life Sciences Review - deliver up an engaging mix of insight, opinion and market intelligence straight from the corporate boardrooms of some of the world’s most high performance economies.

Download our latest country report on 

China

Switzerland

France 

UK

BioPharm Insight is the definitive guide to the global life sciences community. BioPharm Insight provides clients with an information edge by combining a comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists. More info at: www.biopharminsight.com

Venue

Intercontinental At Doral Miami
2505 NW 87th Ave Doral FL, 33172
Tel: 305.468.1400

fallback

Accommodation

For accommodation options near to the venue, please click here.

fallback

Accommodation Preferential Rates

Preferential rates for delegates booking accommodation on the 24th and 25th of October are available at the Intercontinental Doral Miami. 

Single and double rooms are available at $152+ tax per night.  Rates are valid until October 10th, and are based on current availability.

To book please click here.

fallback

2015's Latin America Life Sciences & Healthcare Summit

"It is a great opportunity to interact with industry leaders, get to know best practices, and identify challenges and opportunities for Latin America"
Vanessa Araujo, Instructor of Portuguese, University of Nevada, Reno

"Extraordinary and deep, useful content, great opportunity for networking" 
Lars Atorf, Director & Head of Global Communications, Merck KGaA, Darmstadt

"All the topics addressed are extremely critical and relevant to the industry today and the Summit provides a great forum to engage on these topics"
Eleonora Leone, Director Public Relations and Advocacy Latin America, Sanofi Pasteur Latin America

"A comprehensive and realistic discussion on healthcare in Latin America"
Leonardo Florencio, CEO, ePrimeCare

"Great event for industry outsiders such as myself"
Gina Moreno, Mexico Life Sciences and Health Care Industry Leader, Deloitte

"This forum did not disappoint - as always a quality job. Mr. Ward a wonderful facilitator/moderator"
Miguel Martin de Bustamante, Associate, CBPartners

Further details of the 2015 FT Latin America Life Sciences & Healthcare Summit can be found here >>

fallback

Contact Us

Aneliese Hirst
Media Partner And Press Enquiries
Financial Times
Angela Letinov
Speaking Opportunities
Financial Times
Tim Powell
Sponsorship Opportunities
Financial Times
Zowie Fort
Delegate Booking and Registration Enquiries

Photos

A selection of photographs taken at the event are available to view on our Flicker page here.

FT Latin America Healthcare and Life Sciences Summit   Flickr

fallback